The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models.
 
Aleksandra Franovic
Employment - Bristol-Myers Squibb; Guardant Health; Kinnate Biopharma
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene; Guardant Health
 
Nichol Miller
Employment - Kinnate Biopharma; Pfizer
Stock and Other Ownership Interests - Pfizer
 
Paul Severson
Employment - Kinnate Biopharma; Plexxikon
Stock and Other Ownership Interests - Daiichi Sankyo/UCB Japan; Kinnate Biopharma
Travel, Accommodations, Expenses - Plexxikon
 
Toufike Kanouni
No Relationships to Disclose
 
Toufike Kanouni
Employment - Kinnate Biopharma
Stock and Other Ownership Interests - Kinnate Biopharma
 
Noelito Timple
Employment - Kinnate Biopharma
Stock and Other Ownership Interests - Kinnate Biopharma
Patents, Royalties, Other Intellectual Property - Kinnate Biopharma
 
Ping Jiang
Employment - Kinnate Biopharma; Pfizer
Stock and Other Ownership Interests - Kinnate Biopharma; Pfizer
 
Eric Murphy
Employment - Kinnate Biopharma
Leadership - Kinnate Biopharma
Stock and Other Ownership Interests - Kinnate Biopharma
Patents, Royalties, Other Intellectual Property - Kinnate Biopharma
 
Eric Martin
Employment - Kinnate Biopharma
Stock and Other Ownership Interests - Kinnate Biopharma
Travel, Accommodations, Expenses - Kinnate Biopharma